Do you have your Pyxis/Omnicell/ADC set up to allow user-to-user transfer of controlled substances by anesthesia providers in the OR? E.g. CRNA John pulls fentanyl 100 mcg for an OR case, does not give any to the patient and then goes to lunch. He signs out the med to CRNA Sally in Pyxis.

Thanks,
Will Vincent
Boston Medical Center

Hi everyone - does anyone dilute IVP lorazepam prior to administration? There is a manufacturer recommendation to dilute prior to intravenous administration but I have not seen it done in clinical practice because the volumes are so low (0.5 mL to 1 mL).

Hello,

Does anyone have a hospital policy on multi-dose vials that they are willing to share?

Thank you,

Matthew Beaulac

Hello.

I am new to the med safety role & in need of some expert advice on a process that is new to our facility.

Our anesthesiologists assist with pain managment at our hospital and a new physician has a practice of having nurses dilute dilaudid 1mg in 10mL normal saline and infusing it over 15 minutes to avoid "patient conflation of opioid-induced euphoria vs. true analgesic benefit."

We are looking into using the ADD-vantage system. In watching the Pfizer video, it looks like the plug floats around in the bag after mixing and could potentially block the flow of the fluid during administration. Does anyone use these and have you ever found this to be a problem?

Thank you!

Hello,

There has been quite a bit of discussion around increasing characters required for product searches in ADCs. Have any institutions required minimum characters in CPOE as well? We are an epic institution and curious if others have considered this.

We are preparing for our Leapfrog survey (first one). In such were coming across the need to use Beers List, but have concerns with the amount of alert fatigue it may cause.

Specific questions for those that use it:
1. Do you use what is offered "out of the box" from your EMR? If so which one?
2. Do you treat all settings equally? Hospital, Ambulatory, LTC.
3. How do you reduce the noise to really get at the intended patients? This may be different for each setting.

Hi All - has anyone completed a compare/contrast or gap analysis related to the different manufacturers of infusion pumps? Was hoping to save some time if anyone has already completed this work.

Thanks!

For facilities that utilize ADC-prompted virtual rapid sequence intubation (RSI) kits, what best practices have you implemented? Including what has and hasn't worked.

Can anyone share how they have tackled their LASA policy/lists when it comes to addressing biosimilars and monoclonal antibodies. We think the nomenclature is easily confused and are evaluating possible safety impacts/look-alike, sound-alike risks as more of these products come to market. We would prefer to avoid blanket statements such as adding all monoclonal antibodies are at risk for LASA errors.
Thanks!